PULMONARY EMBOLISM
WHAT’S NEW
PULMONARY EMBOLISM
LEARNING CENTRE
WHAT’S NEW

 
Vascular Surgery / Venous Thromboembolism / What's New


KNOCOUT PE Registry Prospective Cohort: 3-Month Data

KNOCOUT PE registry represents the single largest prospective data set in interventional PE treatment to-date, adding evidence to the already most studied device in the PE space. The registry included a wide range of patients with Intermediate-high and high-risk PE, showing that contemporary clinical practices are moving to low-dose, shorter duration OPTALYSE protocols and with it comes the benefit of both sustained efficacy and an improved safety profile.


HI-PEITHO Trial - First Patient Enrollment
The largest randomised controlled trial on Intervention vs Anticoagulation in Pulmonary Embolism.

HI-PEITHO is a multi-center, prospective, randomized, controlled trial in the U.S. and Europe that will compare the outcomes of ultrasound-facilitated, catheter-directed, thrombolysis plus anticoagulation vs. anticoagulation alone for the treatment of acute, intermediate-high risk pulmonary embolism (PE).


EkoSonic™ Endovascular System
Higher-risk Pulmonary Embolism Thrombolysis Study

HI-PEITHO is a multi-center, prospective, randomized, controlled trial in the U.S. and Europe that will compare the outcomes of ultrasound-facilitated, catheter-directed, low-dose thrombolysis plus anticoagulation vs. anticoagulation alone for the treatment of acute, intermediate-high-risk pulmonary embolisms (PE).


World Thrombosis Day - 2020

Today is World Thrombosis Day. Thrombosis contributes to one in four deaths worldwide, yet it remains under-recognised. Thank you to all physicians and hospitals who shared messages to help raise awareness. In this video, we've compiled some of their messages.


Pulmonary Embolism and Covid-19 | How to handle this new paradigm?

A group of European opinion-leaders in Pulmonary Embolism (PE) came together (virtually) in April to discuss the connection between PE and COVID-19.

Available resources (-)

 

 

Top